Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
36.7M
-
Shares change
-
+1.18M
-
Total reported value, excl. options
-
$4.39B
-
Value change
-
+$170M
-
Put/Call ratio
-
0.84
-
Number of buys
-
101
-
Number of sells
-
-71
-
Price
-
$119.75
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2017
221 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2017.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.7M shares
of 49.6M outstanding shares and own 73.9% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (5.26M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.55M shares), VANGUARD GROUP INC (2.55M shares), ORBIMED ADVISORS LLC (2.43M shares), FMR LLC (2.11M shares), JANUS HENDERSON GROUP PLC (1.89M shares), BlackRock Inc. (1.81M shares), Partner Fund Management, L.P. (1.37M shares), STATE STREET CORP (1.29M shares), and CITADEL ADVISORS LLC (1.05M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.